Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:LGND
- CUSIP: 53220K50
- Web: www.ligand.com
Capitalization:- Market Cap: $2.59 billion
- Outstanding Shares: 20,996,000
Average Prices:- 50 Day Moving Avg: $118.34
- 200 Day Moving Avg: $110.09
- 52 Week Range: $87.50 - $139.79
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 33.39
- P/E Growth: 1.30
Sales & Book Value:- Annual Revenue: $108.59 million
- Price / Sales: 23.89
- Book Value: $18.99 per share
- Price / Book: 6.51
Profitability:- EBIDTA: $51.73 million
- Net Margins: -2.91%
- Return on Equity: 2.57%
- Return on Assets: 1.47%
Debt:- Debt-to-Equity Ratio: 0.07%
- Current Ratio: 0.77%
- Quick Ratio: 0.74%
Misc:- Average Volume: 221,998 shs.
- Beta: 0.97
- Short Ratio: 18.54
Frequently Asked Questions for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
What is Ligand Pharmaceuticals Incorporated's stock symbol?
Ligand Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals Incorporated's earnings last quarter?
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its earnings results on Tuesday, May, 9th. The company reported $0.39 earnings per share for the quarter, missing analysts' consensus estimates of $0.55 by $0.16. The firm had revenue of $29.27 million for the quarter, compared to analyst estimates of $30.25 million. Ligand Pharmaceuticals Incorporated had a positive return on equity of 2.57% and a negative net margin of 2.91%. Ligand Pharmaceuticals Incorporated's revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.63 earnings per share. View Ligand Pharmaceuticals Incorporated's Earnings History.
What guidance has Ligand Pharmaceuticals Incorporated issued on next quarter's earnings?
Ligand Pharmaceuticals Incorporated issued an update on its FY17 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of $2.70 for the period, compared to the Thomson Reuters consensus estimate of $3.12.
Where is Ligand Pharmaceuticals Incorporated's stock going? Where will Ligand Pharmaceuticals Incorporated's stock price be in 2017?
4 equities research analysts have issued 12-month target prices for Ligand Pharmaceuticals Incorporated's stock. Their forecasts range from $103.00 to $160.00. On average, they expect Ligand Pharmaceuticals Incorporated's stock price to reach $133.60 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals Incorporated.
Who are some of Ligand Pharmaceuticals Incorporated's key competitors?
Some companies that are related to Ligand Pharmaceuticals Incorporated include PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), PAREXEL International Corporation (PRXL), Exact Sciences Corporation (EXAS), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX), Sage Therapeutics (SAGE), INC Research Holdings (INCR), Intrexon Corporation (XON), Ironwood Pharmaceuticals (IRWD), FibroGen (FGEN), Blueprint Medicines Corporation (BPMC) and Emergent Biosolutions (EBS).
Who are Ligand Pharmaceuticals Incorporated's key executives?
Ligand Pharmaceuticals Incorporated's management team includes the folowing people:
- Matthew W. Foehr, President, Chief Operating Officer
- John L. Higgins, Chief Executive Officer, Director
- Matthew E. Korenberg, Chief Financial Officer, Vice President - Finance
- Charles S. Berkman J.D., Vice President, General Counsel, Secretary
- John W. Kozarich, Non-Executive Independent Chairman of the Board
- Jason M. Aryeh, Independent Director
- Todd C. Davis, Independent Director
- John L. LaMattina Ph.D., Independent Director
- Sunil Patel, Independent Director
Who owns Ligand Pharmaceuticals Incorporated stock?
Ligand Pharmaceuticals Incorporated's stock is owned by many different of institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (1.84%), Russell Investments Group Ltd. (1.77%), AMI Asset Management Corp (0.66%), Woodstock Corp (0.32%), Fisher Asset Management LLC (0.29%) and Summit Creek Advisors LLC (0.21%). Company insiders that own Ligand Pharmaceuticals Incorporated stock include David M Knott, Jason Aryeh, John L Higgins, John W Kozarich, Matthew W Foehr and Melanie J Herman. View Institutional Ownership Trends for Ligand Pharmaceuticals Incorporated.
Who sold Ligand Pharmaceuticals Incorporated stock? Who is selling Ligand Pharmaceuticals Incorporated stock?
Ligand Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Creative Planning, Independent Portfolio Consultants Inc., Sheets Smith Wealth Management, Parametrica Management Ltd, Fisher Asset Management LLC, BB&T Corp and Court Place Advisors LLC. Company insiders that have sold Ligand Pharmaceuticals Incorporated stock in the last year include Jason Aryeh, John L Higgins, John W Kozarich and Matthew W Foehr. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.
Who bought Ligand Pharmaceuticals Incorporated stock? Who is buying Ligand Pharmaceuticals Incorporated stock?
Ligand Pharmaceuticals Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Conestoga Capital Advisors LLC, AMI Asset Management Corp, Aperio Group LLC, State of Alaska Department of Revenue, Woodstock Corp, Congress Asset Management Co. MA and Strs Ohio. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.
How do I buy Ligand Pharmaceuticals Incorporated stock?
Shares of Ligand Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals Incorporated's stock price today?
One share of Ligand Pharmaceuticals Incorporated stock can currently be purchased for approximately $123.54.
MarketBeat Community Rating for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $133.60 (8.14% upside) |
Analysts' Ratings History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/17/2017 | Deutsche Bank AG | Reiterated Rating | Hold | $100.00 -> $103.00 | Low |  |
| 5/22/2017 | Roth Capital | Set Price Target | Buy | $120.00 | Low | |
| 9/28/2016 | CJS Securities | Lower Price Target | Outperform | $130.00 -> $125.00 | N/A | |
| 10/5/2016 | Craig Hallum | Boost Price Target | | $150.00 -> $160.00 | N/A | |
| 10/5/2016 | HC Wainwright | Reiterated Rating | Buy | $146.00 -> $160.00 | N/A | |
| 4/13/2016 | Stephens | Initiated Coverage | Overweight | $150.00 | N/A | |
| 3/11/2016 | Sidoti | Initiated Coverage | Buy | $140.00 | N/A | |
(Data available from 7/26/2015 forward)
Earnings History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Earnings History by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | Q1 2017 | $0.55 | $0.39 | $30.25 million | $29.27 million | View | Listen | |
| 2/23/2017 | Q416 | $1.19 | ($0.15) | $40.34 million | $38.20 million | View | N/A | |
| 11/3/2016 | Q316 | $0.59 | $0.62 | $23.64 million | $21.62 million | View | N/A | |
| 8/4/2016 | Q216 | $0.40 | $0.50 | $18.12 million | $19.50 million | View | N/A | |
| 5/4/2016 | Q116 | $0.67 | $0.97 | $26.45 million | $29.60 million | View | N/A | |
| 2/10/2016 | Q415 | $0.51 | $0.66 | $24.71 million | $21.20 million | View | Listen | |
| 11/9/2015 | Q315 | $0.42 | $0.56 | $17.80 million | $17.70 million | View | N/A | |
| 8/4/2015 | Q215 | $0.40 | $1.63 | $17.00 million | $18.42 million | View | N/A | |
| 5/11/2015 | Q115 | $0.12 | $0.33 | $13.50 million | $14.60 million | View | Listen | |
| 2/9/2015 | Q414 | $0.48 | $0.48 | $23.88 million | $23.00 million | View | N/A | |
| 10/27/2014 | Q314 | $0.21 | $0.19 | $14.60 million | $15.00 million | View | Listen | |
| 8/4/2014 | Q214 | $0.14 | $0.24 | $9.73 million | $10.60 million | View | N/A | |
| 5/7/2014 | Q114 | $0.25 | $0.35 | $13.63 million | $16.00 million | View | N/A | |
| 2/11/2014 | Q413 | $0.19 | $0.35 | $13.72 million | $14.70 million | View | N/A | |
| 10/30/2013 | Q213 | $0.07 | $0.12 | $10.81 million | $13.00 million | View | N/A | |
| 8/1/2013 | Q2 2013 | $0.06 | $0.07 | $9.48 million | $9.58 million | View | N/A | |
| 5/8/2013 | Q1 2013 | $0.09 | $0.16 | $10.00 million | $11.70 million | View | N/A | |
| 2/13/2013 | Q4 2012 | | $0.19 | $12.90 million | $13.60 million | View | N/A | |
| 11/5/2012 | Q312 | $0.04 | ($0.01) | $8.40 million | $6.40 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)2017 EPS Consensus Estimate: $2.60
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.43 | $0.43 | $0.43 |
| Q2 2017 | 1 | $0.60 | $0.60 | $0.60 |
| Q3 2017 | 1 | $0.75 | $0.75 | $0.75 |
| Q4 2017 | 1 | $0.82 | $0.82 | $0.82 |
(Data provided by Zacks Investment Research)
Dividend History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Insider Ownership Percentage: 14.70%
Insider Trades by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/21/2017 | John L Higgins | CEO | Sell | 4,666 | $120.00 | $559,920.00 | |
| 6/9/2017 | John L Higgins | CEO | Sell | 12,000 | $114.87 | $1,378,440.00 | |
| 5/12/2017 | Jason Aryeh | Director | Sell | 37,247 | $110.76 | $4,125,477.72 | |
| 5/12/2017 | Matthew W Foehr | Insider | Sell | 5,621 | $112.20 | $630,676.20 | |
| 3/20/2017 | John L Higgins | CEO | Sell | 4,000 | $109.10 | $436,400.00 | |
| 3/2/2017 | Matthew W Foehr | Insider | Sell | 6,879 | $103.39 | $711,219.81 | |
| 2/28/2017 | Jason Aryeh | Director | Sell | 32,000 | $106.35 | $3,403,200.00 | |
| 11/25/2016 | Jason Aryeh | Director | Sell | 18,479 | $107.31 | $1,982,981.49 | |
| 11/18/2016 | Jason Aryeh | Director | Sell | 6,330 | $105.28 | $666,422.40 | |
| 9/22/2016 | John L Higgins | CEO | Sell | 3,000 | $117.34 | $352,020.00 | |
| 9/7/2016 | John W Kozarich | Director | Sell | 1,000 | $115.00 | $115,000.00 | |
| 9/1/2016 | John W Kozarich | Director | Sell | 1,666 | $105.40 | $175,596.40 | |
| 8/1/2016 | John W Kozarich | Director | Sell | 1,000 | $137.57 | $137,570.00 | |
| 7/1/2016 | John W Kozarich | Director | Sell | 1,000 | $121.40 | $121,400.00 | |
| 6/1/2016 | John W Kozarich | Director | Sell | 1,000 | $117.42 | $117,420.00 | |
| 5/18/2016 | Melanie J Herman | Director | Sell | 334 | $120.50 | $40,247.00 | |
| 5/6/2016 | Jason Aryeh | Director | Sell | 25,000 | $119.20 | $2,980,000.00 | |
| 5/2/2016 | John W Kozarich | Director | Sell | 1,000 | $121.57 | $121,570.00 | |
| 4/6/2016 | John W Kozarich | Director | Sell | 5,000 | $115.00 | $575,000.00 | |
| 3/17/2016 | Matthew W Foehr | COO | Sell | 6,400 | $96.70 | $618,880.00 | |
| 3/8/2016 | Jason Aryeh | Director | Sell | 6,129 | $101.18 | $620,132.22 | |
| 3/7/2016 | John L Higgins | CEO | Sell | 10,833 | $102.47 | $1,110,057.51 | |
| 1/20/2016 | John W. Kozarich | Director | Sell | 1,666 | $94.94 | $158,170.04 | |
| 11/11/2015 | Melanie J. Herman | Director | Sell | 7,719 | $101.00 | $779,619.00 | |
| 8/17/2015 | David M Knott | Director | Sell | 4,000 | $95.98 | $383,920.00 | |
| 8/13/2015 | David M Knott | Director | Sell | 49,800 | $96.26 | $4,793,748.00 | |
| 7/10/2015 | Charles S Berkman | VP | Sell | 14,067 | $99.14 | $1,394,602.38 | |
| 6/26/2015 | Matthew W Foehr | COO | Sell | 12,500 | $100.97 | $1,262,125.00 | |
| 6/22/2015 | Matthew W Foehr | COO | Sell | 23,046 | $96.45 | $2,222,786.70 | |
| 6/10/2015 | Melanie J Herman | CFO | Sell | 4,125 | $93.50 | $385,687.50 | |
| 6/9/2015 | John L Higgins | CEO | Sell | 10,000 | $92.88 | $928,800.00 | |
| 6/4/2015 | Jason Aryeh | Director | Sell | 1,640 | $92.68 | $151,995.20 | |
| 5/20/2015 | Jason Aryeh | Director | Sell | 9,240 | $87.34 | $807,021.60 | |
| 5/14/2015 | Nishan M Desilva | CFO | Sell | 68,363 | $83.91 | $5,736,339.33 | |
| 3/19/2015 | Sunil Patel | Director | Sell | 4,591 | $74.42 | $341,662.22 | |
| 2/10/2015 | Nishan M Desilva | VP | Sell | 2,300 | $56.34 | $129,582.00 | |
| 10/15/2014 | John W Kozarich | Director | Buy | 2,000 | $45.68 | $91,360.00 | |
| 10/9/2014 | Jason Aryeh | Director | Buy | 11,000 | $42.99 | $472,890.00 | |
| 8/15/2014 | John L Higgins | CEO | Buy | 1,000 | $54.97 | $54,970.00 | |
| 6/9/2014 | Melanie J Herman | Director | Sell | 1,100 | $69.68 | $76,648.00 | |
| 5/27/2014 | Charles S Berkman | VP | Sell | 7,166 | $66.90 | $479,405.40 | |
| 3/25/2014 | Bvf Partners P/Il | Insider | Sell | 78,226 | $70.09 | $5,482,860.34 | |
| 3/19/2014 | Todd Davis | Director | Sell | 7,500 | $79.57 | $596,775.00 | |
| 3/18/2014 | John Lamattina | Director | Sell | 5,000 | $78.83 | $394,150.00 | |
| 2/20/2014 | Bvf Partners P/Il | major shareholder | Sell | 422,900 | $73.81 | $31,214,249.00 | |
| 2/18/2014 | David Knott | Director | Sell | 41,900 | $75.71 | $3,172,249.00 | |
| 2/14/2014 | Jason Aryeh | Director | Sell | 40,320 | $76.44 | $3,082,060.80 | |
| 2/14/2014 | Matthew Foehr | COO | Sell | 22,500 | $79.54 | $1,789,650.00 | |
| 12/12/2013 | Matthew Foehr | COO | Sell | 6,000 | $53.40 | $320,400.00 | |
| 12/6/2013 | John Sharp | CFO | Sell | 6,000 | $56.08 | $336,480.00 | |
| 10/18/2013 | John L Higgins | CEO | Sell | 10,000 | $55.00 | $550,000.00 | |
| 9/23/2013 | Bvf Partners P/Il | major shareholder | Sell | 359,023 | $44.50 | $15,976,523.50 | |
| 9/12/2013 | David Knott | Director | Sell | 160,000 | $46.78 | $7,484,800.00 | |
| 8/30/2013 | Charles Berkman | VP | Sell | 28,323 | $47.54 | $1,346,475.42 | |
| 8/16/2013 | Charles Berkman | VP | Sell | 14,583 | $42.63 | $621,673.29 | |
| 8/16/2013 | John Higgins | CEO | Sell | 10,000 | $42.85 | $428,500.00 | |
| 8/16/2013 | John Sharp | CFO | Sell | 7,500 | $42.75 | $320,625.00 | |
| 6/28/2013 | Matthew W Foehr | COO | Buy | 1,059 | $17.36 | $18,384.24 | |
| 5/10/2013 | Charles S Berkman | VP | Sell | 4,000 | $26.66 | $106,640.00 | |
| 1/23/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 39,600 | $19.78 | $783,288.00 | |
| 12/14/2012 | Bvf Partners L P/Il | Major Shareholder | Buy | 5,386 | $18.63 | $100,341.18 | |
| 12/6/2012 | Bvf Partners L P/Il | Major Shareholder | Buy | 50,100 | $17.94 | $898,794.00 | |
| 12/5/2012 | John L Higgins | CEO | Buy | 2,000 | $18.03 | $36,060.00 | |
| 10/31/2012 | Bvf Partners L P/Il | Major Shareholder | Buy | 16,591 | $15.19 | $252,017.29 | |
| 8/29/2012 | David M Knott | Director | Buy | 2,743 | $16.36 | $44,875.48 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Latest Headlines for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
| Source: |
|
| Date | Headline |
|---|
 | Ligand Pharmaceuticals Incorporated (LGND) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 24 at 10:17 AM |
| Ligand Pharmaceuticals Incorporated (LGND) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - July 23 at 4:21 PM |
 | Ligand to Report Second Quarter 2017 Results on August 7th
finance.yahoo.com - July 21 at 1:19 AM |
 | Ligand Pharma (LGND) Enters Pact with Amgen for Rights to Use Captisol in Formulation of AMG 330
www.streetinsider.com - July 18 at 9:40 PM |
| Ligand Signs Agreement with Amgen, Grants Rights to Captisol
finance.yahoo.com - July 18 at 4:38 PM |
| Invest Like "Royalty" With These 3 Stocks
finance.yahoo.com - July 18 at 4:38 PM |
| Ligand Pharma (LGND) Enters Pact with Amgen for Rights to Use Captisol in Formulation of AMG 330 - StreetInsider.com
www.streetinsider.com - July 18 at 6:14 AM |
| Deutsche Bank AG Raises Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Price Target to $103.00
www.americanbankingnews.com - July 17 at 7:15 PM |
| Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330
finance.yahoo.com - July 17 at 12:55 PM |
| Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expected to Post Quarterly Sales of $23.54 Million
www.americanbankingnews.com - July 16 at 7:54 AM |
| $0.25 Earnings Per Share Expected for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) This Quarter
www.americanbankingnews.com - July 14 at 6:24 PM |
| Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 4:52 PM |
| Ligand Pharmaceuticals Incorporated (LGND) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 27 at 8:44 AM |
| Ligand Pharmaceuticals Incorporated (LGND) Raised to Hold at ValuEngine
www.americanbankingnews.com - June 24 at 11:32 PM |
| Ligand Pharmaceuticals Incorporated (LGND) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - June 23 at 8:20 PM |
| Ligand Pharmaceuticals Incorporated (LGND) CEO Sells $559,920.00 in Stock
www.americanbankingnews.com - June 23 at 7:15 PM |
| Ligand Gets Milestone Payment on Partner Drug FDA Approval
finance.yahoo.com - June 22 at 12:33 PM |
| Ligand Pharmaceuticals Incorporated (LGND) Expected to Post Quarterly Sales of $23.39 Million
www.americanbankingnews.com - June 22 at 10:12 AM |
 | Ligand Pharma Earns Milestone Payment On FDA Approval Of Baxdela - Quick Facts
www.nasdaq.com - June 21 at 5:31 AM |
| Ligand Pharmaceuticals Incorporated (LGND) Expected to Post Earnings of $0.23 Per Share
www.americanbankingnews.com - June 20 at 4:06 PM |
| Ligand Pharma (LGND) Partner Melinta Therapeutics Reports FDA ... - StreetInsider.com
www.streetinsider.com - June 20 at 3:49 PM |
| Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
finance.yahoo.com - June 20 at 3:49 PM |
| Why Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - June 13 at 8:21 AM |
| Why Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report?
finance.yahoo.com - June 13 at 8:21 AM |
| Ligand Pharmaceuticals Inc. (LGND) CEO John L. Higgins Sells 12,000 Shares
www.americanbankingnews.com - June 9 at 10:08 PM |
| Featured Company News - Viking Therapeutics' VK2809 Shows Encouraging Results in Non-Alcoholic Steatohepatitis
finance.yahoo.com - June 8 at 9:04 AM |
| Ligand Pharma (LGND) to Receive $10M Royalty Fee Following Sale of Certain Product Rights by CorMatrix to Aziyo ... - StreetInsider.com
www.streetinsider.com - June 3 at 12:41 AM |
| Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology
finance.yahoo.com - June 1 at 7:06 PM |
| Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : June 1, 2017
finance.yahoo.com - June 1 at 8:54 AM |
| Ligand Pharma (LGND) to Receive $10M Royalty Fee Following Sale of Certain Product Rights by CorMatrix to Aziyo Biologics
www.streetinsider.com - May 31 at 11:42 PM |
| Ligand (LGND) Signs Licensing Deal with xCella Biosciences
finance.yahoo.com - May 31 at 6:40 PM |
| Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix
finance.yahoo.com - May 31 at 6:40 PM |
| Ligand Pharmaceuticals Inc. (LGND) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 31 at 7:50 AM |
| Ligand Pharma (LGND) Announces Worldwide OmniAb Platform License Agreement With xCella Biosciences - StreetInsider.com
www.streetinsider.com - May 31 at 5:19 AM |
| Ligand Pharma (LGND) Announces Worldwide OmniAb Platform License Agreement With xCella Biosciences
www.streetinsider.com - May 30 at 10:16 AM |
| Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences
finance.yahoo.com - May 30 at 10:16 AM |
| $23.92 Million in Sales Expected for Ligand Pharmaceuticals Inc. (LGND) This Quarter
www.americanbankingnews.com - May 27 at 8:40 AM |
| $0.23 EPS Expected for Ligand Pharmaceuticals Inc. (LGND) This Quarter
www.americanbankingnews.com - May 25 at 12:22 PM |
| Ligand Pharmaceuticals Inc. (LGND) PT Set at $120.00 by Roth Capital
www.americanbankingnews.com - May 23 at 6:58 PM |
| ETFs with exposure to Ligand Pharmaceuticals, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 5:39 PM |
| Ligand to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - May 22 at 10:21 AM |
| Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 10:49 AM |
| Matthew W. Foehr Sells 5,621 Shares of Ligand Pharmaceuticals Inc. (LGND) Stock
www.americanbankingnews.com - May 15 at 10:35 PM |
| Ligand Pharmaceuticals Inc. (LGND) Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - May 15 at 9:14 AM |
| Ligand Pharmaceuticals Inc. (LGND) Director Jason Aryeh Sells 37,247 Shares
www.americanbankingnews.com - May 13 at 7:22 AM |
| Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates - Nasdaq
www.nasdaq.com - May 11 at 6:46 PM |
| Ligand Pharmaceuticals Inc Q1 Earnings Fall 7%
www.nasdaq.com - May 10 at 12:52 PM |
| Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates
finance.yahoo.com - May 10 at 12:52 PM |
| Edited Transcript of LGND earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 12:52 PM |
| Ligand Pharmaceuticals Inc. (LGND) Posts Earnings Results, Misses Estimates By $0.15 EPS
www.americanbankingnews.com - May 9 at 10:44 PM |
Ligand Pharmaceuticals Incorporated (LGND) Chart for Wednesday, July, 26, 2017
